参考文献/References:
[1] Tuttle KR,Bakris GL,Bilous RW,et al.Diabetic kidney disease:a report from an ADA consensus conference[J].Am J Kidney Dis,2014,64(4):510-533.DOI:10.1053/j.ajkd.2014.08.001.
[2] KDOQI.KDOQI clinical practice guidelines and clinical practice recommendations for diabetes and chronic kidney disease[J].Am J Kidney Dis,2007,49(2 Suppl 2):S12-S154.DOI:10.1053/j.ajkd.2006.12.005.
[3] American Diabetes Association.11.Microvascular Complications and Foot Care:Standards of Medical Care in Diabetes-2019[J].Diabetes Care,2019,42(Suppl 1):S124-S138.DOI:10.2337/dc19-S011.
[4] Floege J,Barbour SJ,Cattran DC,et al.Management and treatment of glomerular diseases(part 1):conclusions from a Kidney Disease: Improving Global Outcomes(KDIGO)Controversies Conference[J].Kidney Int,2019,95(2):268-280.DOI:10.1016/j.kint.2018.10.018.
[5] 中华医学会糖尿病学分会微血管并发症学组.中国糖尿病肾脏病防治指南(2021年版)[J].中华糖尿病杂志,2021,13(8):762-784.DOI:10.3760/cma.j.cn115791-20210706-00369.
[6] Yamanouchi M,Mori M,Hoshino J,et al.Retinopathy progression and the risk of end-stage kidney disease:results from a longitudinal Japanese cohort of 232 patients with type 2 diabetes and biopsy-proven diabetic kidney disease[J].BMJ Open Diabetes Res Care,2019,7(1):e000726.DOI:10.1136/bmjdrc-2019-000726.
[7] He F,Xia X,Wu XF,et al.Diabetic retinopathy in predicting diabetic nephropathy in patients with type 2 diabetes and renal disease:a meta-analysis[J].Diabetologia,2013,56(3):457-466.DOI:10.1007/s00125-012-2796-6.
[8] Chen C,Wang C,Hu C,et al.Normoalbuminuric diabetic kidney disease[J].Front Med,2017,11(3):310-318.DOI:10.1007/s11684-017-0542-7.
[9] Tsalamandris C,Allen TJ,Gilbert RE,et al.Progressive decline in renal function in diabetic patients with and without albuminuria[J].Diabetes,1994,43(5):649-655.DOI:10.2337/diab.43.5.649.
[10] 孙林,陈超.加强对正常蛋白尿糖尿病肾脏疾病的认识[J].中华肾病研究电子杂志,2016,5(4):145-151.DOI:10.3877/cma.j.issn.2095-3216.2016.04.001.
[11] Lacquaniti A,Donato V,Pintaudi B,et al."Normoalbuminuric"diabetic nephropathy:tubular damage and NGAL[J].Acta Diabetol,2013,50(6):935-942.DOI:10.1007/s00592-013-0485-7.
[12] Mottl AK,Kwon KS,Mauer M,et al.Normoalbuminuric diabetic kidney disease in the U.S. population[J].J Diabetes Complications,2013,27(2):123-127.DOI:10.1016/j.jdiacomp.2012.09.010.
[13] Macisaac RJ,Jerums G.Diabetic kidney disease with and without albuminuria[J].Curr Opin Nephrol Hypertens,2011,20(3):246-257.DOI:10.1097/MNH.0b013e3283456546.
[14] Yu ASL,Chertow GM,Luyckx VA,et al.Brenner & Rector's the kidney[M].11th ed,Philadelphia,PA:Elsevier,2019.
[15] Nowak N.Protective factors as biomarkers and targets for prevention and treatment of diabetic nephropathy:from current human evidence to future possibilities[J].J Diabetes Investig,2020,11(5):1085-1096.DOI:10.1111/jdi.13257.
[16] Zhang Y,Yang J,Zheng M,et al.Clinical characteristics and predictive factors of subclinical diabetic nephropathy[J].Exp Clin Endocrinol Diabetes,2015,123(2):132-138.DOI:10.1055/s-0034-1396810.
[17] Kidney Disease:Improving Global Outcomes(KDIGO)CKD Work Group.KDIGO 2012 clinical practice guideline for the evaluation and management of chronic kidney disease[J].Kidney Int Suppl,2013,3(1):S1-S150.DOI:10.1038/kisup.2012.73.
[18] American Diabetes Association.2.Classification and Diagnosis of Diabetes[J].Diabetes Care,2016,39 Suppl 1:S13-S22.DOI:10.2337/dc16-S005.
[19] Perkins BA,Ficociello LH,Ostrander BE,et al.Microalbuminuria and the risk for early progressive renal function decline in type 1 diabetes[J].J Am Soc Nephrol,2007,18(4):1353-1361.DOI:10.1681/ASN.2006080872.
[20] American Diabetes Association.16.Diabetes advocacy:standards of medical care in diabetes-2019[J].Diabetes Care,2019,42(Suppl 1):S182-S183.DOI:10.2337/dc19-S016.
[21] Ikizler TA,Burrowes JD,Byham-Gray LD,et al.KDOQI clinical practice guideline for nutrition in CKD:2020 update[J].Am J Kidney Dis,2020,76(3 Suppl 1):S1-S107.DOI:10.1053/j.ajkd.2020.05.006.
[22] Kidney Disease:Improving Global Outcomes(KDIGO)CKD Work Group.KDIGO 2024 clinical practice guideline for the evaluation and management of chronic kidney disease[J].Kidney Int,2024,105(4S):S117-S314.DOI:10.1016/j.kint.2023.10.018.
[23] Tuttle KR,Bakris GL,Bilous RW,et al.Diabetic kidney disease:a reportfrom an ADA consensus conference[J].Diabetes Care,2014,37(10):2864-2883.DOI:0.2337/dc14-1296.
[24] 中华医学会肾脏病学分会专家组.糖尿病肾脏疾病临床诊疗中国指南[J].中华肾脏病杂志,2021,37(3):255-304.DOI:10.3760/cma.j.cn441217-20201125-00041.
[25] McMahon EJ,Campbell KL,Bauer JD,et al.Altered dietary salt intake for people with chronic kidney disease[J].Cochrane Database Syst Rev,2021,6(6):CD010070.DOI:10.1002/14651858.CD010070.
[26] Lambers Heerspink HJ,Holtkamp FA,Parving HH,et al.Moderation of dietary sodium potentiates the renal and cardiovascular protective effects of angiotensin receptor blockers[J].Kidney Int,2012,82(3):330-337.DOI:10.1038/ki.2012.74.
[27] 高忠爱,杨波,郑妙艳,等.糖尿病合并大量蛋白尿的中西医治疗策略[J].国际内分泌代谢杂志,2021,41(6):583-586.DOI:10.3760/cma.j.cn121383-20210930-09088.
[28] Jiang W,Wang J,Shen X,et al.Establishment and validation of a risk prediction model for early diabetic kidney disease based on a systematic review and meta-analysis of 20 cohorts[J].Diabetes Care,2020,43(4):925-933.DOI:10.2337/dc19-1897.
[29] Gao Z,Wang Z,Zhu H,et al.Hyperinsulinemia contributes to impaired-glucose-tolerance-induced renal injury via mir-7977/SIRT3 signaling[J].Ther Adv Chronic Dis,2020,11:20406223209 16008.DOI:10.1177/2040622320916008.
[30] Zhang Y,Yang S,Cui X,et al.Hyperinsulinemia can cause kidney disease in the IGT stage of OLETF rats via the INS/IRS-1/PI3-K/Akt signaling pathway[J].J Diabetes Res,2019,2019:4709715.DOI:10.1155/2019/4709715.